Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Achaogen, Inc.AKAO · Entity 158957 | Chief Financial Officer | June 26, 2018 | June 28, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Achaogen, Inc.
Report date June 26, 2018 · Filed June 28, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,748 |
Last balance in matching sequence
After 2018-06-26 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-06-26 · Grant · Acquired 860 · Balance 48,046 F1: On February 8, 2018, the issuer granted the reporting person Restricted Stock Units ("RSUs") and a stock option that each vest upon the achievement of certain milestones. On June 26, 2018, one of the milestones was achieved, resulting in vesting of a portion of the RSUs and shares subject to the option. F2: Includes 31,730 RSUs. Row 2 · 2018-06-26 · Sale · Disposed 298 · Balance 47,748 F3: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of RSUs of the Issuer. F2: Includes 31,730 RSUs. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.64 · Expires 2028-02-08 | Direct | 4,000 |
Reported balance
After 2018-06-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-06-26 · Grant · Acquired 4,000 · Balance 4,000 F1: On February 8, 2018, the issuer granted the reporting person Restricted Stock Units ("RSUs") and a stock option that each vest upon the achievement of certain milestones. On June 26, 2018, one of the milestones was achieved, resulting in vesting of a portion of the RSUs and shares subject to the option. F4: The option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 8, 2018, the issuer granted the reporting person Restricted Stock Units ("RSUs") and a stock option that each vest upon the achievement of certain milestones. On June 26, 2018, one of the milestones was achieved, resulting in vesting of a portion of the RSUs and shares subject to the option.
F2: Includes 31,730 RSUs.
F3: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of RSUs of the Issuer.
F4: The option is fully vested and exercisable.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Crinetics Pharmaceuticals, Inc.
Report date September 01, 2026 · Filed September 01, 2026
Section 16 reporting ended · disclosed 2026-09-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-01 · Disposition to issuer · Disposed 7,956 · Balance 71,471 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). Row 2 · 2026-09-01 · Disposition to issuer · Disposed 71,471 · Balance 0 F2: The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.75 · Expires 2035-03-09 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-01 · Disposition to issuer · Disposed 80,000 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.79 · Expires 2036-02-23 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-01 · Disposition to issuer · Disposed 50,000 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration").
F2: The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding.
F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.
F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.
Revance Therapeutics, Inc.
Report date February 04, 2025 · Filed February 06, 2025
Section 16 reporting ended · disclosed 2025-02-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-02-06 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2025-02-04 · Other · Disposed 97,999 · Balance 103,555 F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. Row 2 · 2025-02-06 · Disposition to issuer · Disposed 103,555 · Balance 0 F2: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") award then outstanding and not vested was canceled and converted into the right to receive an amount in cash, without interest thereon and subject to applicable withholding taxes, equal to the product of the Per Share Price and the total number of Shares subject to such unvested RSU award as of immediately prior to the Effective Time (as defined in the Merger Agreement). Row 3 · 2025-02-06 · Grant · Acquired 20,883 · Balance 20,883 F3: Represents a deemed acquisition of the Shares underlying a portion of the performance-based restricted stock units ("PSUs") granted on January 31, 2023, pursuant to the terms of the Merger Agreement. Row 4 · 2025-02-06 · Disposition to issuer · Disposed 20,883 · Balance 0 F4: Pursuant to the Merger Agreement, each PSU award then outstanding and not vested was canceled and converted into the right to receive a lump sum cash payment, without interest thereon and subject to applicable withholding taxes, equal to the product of (i) the Per Share Price multiplied by (ii) the number of Shares subject to such PSU award (with the performance metrics deemed achieved as set forth in the Merger Agreement). |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer.
F2: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") award then outstanding and not vested was canceled and converted into the right to receive an amount in cash, without interest thereon and subject to applicable withholding taxes, equal to the product of the Per Share Price and the total number of Shares subject to such unvested RSU award as of immediately prior to the Effective Time (as defined in the Merger Agreement).
F3: Represents a deemed acquisition of the Shares underlying a portion of the performance-based restricted stock units ("PSUs") granted on January 31, 2023, pursuant to the terms of the Merger Agreement.
F4: Pursuant to the Merger Agreement, each PSU award then outstanding and not vested was canceled and converted into the right to receive a lump sum cash payment, without interest thereon and subject to applicable withholding taxes, equal to the product of (i) the Per Share Price multiplied by (ii) the number of Shares subject to such PSU award (with the performance metrics deemed achieved as set forth in the Merger Agreement).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2022 Filed May 16, 2023 20:29 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 42,349 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-23-000075 · wf-form4_168428336033050.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,430 F1 · kind: Represents settlement of a performance-based restricted stock unit ("PSU") granted on February 2, 2022. On May 12, 2023, the Issuer's Compensation Committee certified 100% of the PSUs eligible to vest based on pre-established criteria related to the price of the Issuer's common stock. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 20:58 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | OtherCommon Stock | 404 | $13.87 | $5,604.29 |
DisclosureSEC source: 0001479290-22-000002 · wf-form4_164134789553273.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,056 F1 · kind: These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan (the "Plan") on December 31,2021 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 17:31 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 1,556 | $15.92 | $24,771.52 |
DisclosureSEC source: 0001479290-21-000177 · wf-form4_163978024325249.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,652 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on December 15, 2021, to satisfy tax withholding obligations that arose in connection with the vesting of 4,500 shares of a Restricted Stock award ("RSA") for 18,000 shares. The RSA vests in four equal annual installments from December 15, 2018, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Inducement Plan) on each vesting date. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 19:53 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | OtherCommon Stock | 446 | $24.09 | $10,743.69 |
DisclosureSEC source: 0001479290-21-000132 · wf-form4_162527001681770.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,208 F1 · kind: These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2021 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 15, 2021 Filed Feb 19, 2021 20:15 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 1,973 | $28.97 | $57,157.81 |
DisclosureSEC source: 0001479290-21-000047 · wf-form4_161378368820459.xml · nonDerivative · entry 2 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,762 F3 · shares: Represents the number of shares withheld by and surrendered to the Issuer on February 15, 2021, to satisfy tax withholding obligations that arose in connection with the vesting of the Restricted Stock award ("RSA") for 16,500 shares. The RSA vests in three equal annual installments from February 15, 2020, subject to Mr. Schilke's Continuous Service (as defined in the Plan) on each vesting date. F2 · price: The fair market value was determined on February 12, 2021 pursuant to the Plan. Read SEC document |
| February 15, 2021 Filed Feb 19, 2021 20:15 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 684 | $28.97 | $19,815.48 |
DisclosureSEC source: 0001479290-21-000047 · wf-form4_161378368820459.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,735 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on February 15, 2021, to satisfy tax withholding obligations that arose in connection with the vesting of the Restricted Stock award ("RSA") for 5,000 shares. The RSA vests in three equal annual installments from February 15, 2019, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan.")) on each vesting date. F2 · price: The fair market value was determined on February 12, 2021 pursuant to the Plan. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:15 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantEmployee Stock Option (Right to Buy) · Derivative | 40,925 | $0.00 Strike: $28.01 | $0.00 |
DisclosureSEC source: 0001479290-21-000035 · wf-form4_161249134328472.xml · derivative · entry 2 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,925 Underlying: Common Stock · 40,925 shares Expires 2031-02-01 F2 · derivative.exercise_date: The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from February 2, 2021, subject to Mr. Schilke's Continuous Service (as defined in the Plan) on each vesting date. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:15 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 22,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-21-000035 · wf-form4_161249134328472.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,419 F1 · shares: The shares subject to the Restricted Stock award shall vest in three (3) equal annual installments beginning from March 15, 2021, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date. Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 20:02 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | OtherCommon Stock | 493 | $21.36 | $10,530.73 |
DisclosureSEC source: 0001479290-21-000009 · wf-form4_160980856502255.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,799 F1 · kind: These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2020 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 15, 2020 Filed Dec 22, 2020 20:39 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 1,556 | $26.75 | $41,623.00 |
DisclosureSEC source: 0001479290-20-000118 · wf-form4_160868756377806.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,306 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on December 15, 2020, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award ("RSA") for 4,500 shares. The RSA vests in four equal annual installments from December 15, 2018, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Inducement Plan) on each vesting date. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 20:32 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 5,446 | $25.14 | $136,912.44 |
DisclosureSEC source: 0001628280-20-014242 · wf-form4_160168515859266.xml · nonDerivative · entry 2 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,862 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on September 30, 2020, to satisfy tax withholding obligations that arose in connection with the vesting of the PSA. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 20:32 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 15,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-014242 · wf-form4_160168515859266.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,308 F1 · shares: Represents shares of Common Stock received upon partial settlement of a performance share award (the "PSA") on September 30, 2020. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:18 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | OtherCommon Stock | 763 | $13.80 | $10,525.97 |
DisclosureSEC source: 0001479290-20-000076 · wf-form4_159373545085161.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,558 F1 · kind: These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2020 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 20:21 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 576 | $25.33 | $14,590.08 |
DisclosureSEC source: 0001479290-20-000031 · wf-form4_158216166821994.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,795 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on February 15, 2020, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock Award ("RSA") for 1,666 shares. The RSA vests in three equal annual installments from February 15, 2019, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan")) on each vesting date. F2 · price: The fair market value was determined on February 14, 2020 pursuant to the Plan. Read SEC document |
| January 23, 2020 Filed Jan 24, 2020 20:21 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantEmployee Stock Option (Right to Buy) · Derivative | 97,500 | $22.32 Strike: $22.32 | $2,176,200.00 |
DisclosureSEC source: 0001479290-20-000019 · wf-form4_157991525885149.xml · derivative · entry 2 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,500 Underlying: Common Stock · 97,500 shares Expires 2030-01-22 F2 · derivative.exercise_date: The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from January 23, 2020, subject to Mr. Schilke's Continuous Service (as defined in the Plan) on each vesting date. Read SEC document |
| January 23, 2020 Filed Jan 24, 2020 20:21 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 16,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-20-000019 · wf-form4_157991525885149.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,371 F1 · shares: The shares subject to the Restricted Stock Award shall vest in three (3) equal annual installments beginning from February 15, 2020, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan(the "Plan")) on each vesting date. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 18:42 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | OtherCommon Stock | 504 | $10.82 | $5,453.28 |
DisclosureSEC source: 0001479290-20-000002 · wf-form4_157809490379524.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,871 F1 · kind: These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan (the "Plan") on December 31, 2019 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Mr. Schilke purchased the maximum number of shares allowable under the Issuer's Plan and Internal Revenue Code Section 423(b)(8) for the period ended December 31, 2019. Read SEC document |
| December 15, 2019 Filed Dec 17, 2019 19:57 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 1,556 | $15.99 | $24,880.44 |
DisclosureSEC source: 0001479290-19-000115 · wf-form4_157663065876390.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,367 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on December 15, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award ("RSA") for 4,500 shares. The RSA vests in four equal annual installments from December 15, 2018, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Inducement Plan) on each vesting date. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 21:16 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | OtherCommon Stock | 923 | $11.02 | $10,175.61 |
DisclosureSEC source: 0001479290-19-000077 · wf-form4_156211658648634.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,923 F1 · kind: These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on June 28, 2019 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 21:00 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $17.23 | $0.00 |
DisclosureSEC source: 0001479290-19-000017 · wf-form4_154846803275133.xml · derivative · entry 2 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-01-23 F2 · derivative.exercise_date: The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from January 24, 2019, subject to Mr. Schilke's Continuous Service (as defined in the Plan) on each vesting date. Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 21:00 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-19-000017 · wf-form4_154846803275133.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 F1 · shares: The shares subject to the Restricted Stock award shall vest in three (3) equal annual installments beginning from February 15, 2019, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan")) on each vesting date. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 20:31 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $24.96 | $0.00 |
DisclosureSEC source: 0001479290-18-000112 · wf-form4_154164068216658.xml · derivative · entry 2 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-11-04 F2 · derivative.exercise_date: The shares subject to the stock option shall vest over a period of four years commencing on November 5, 2018, with 25% vesting on the annual anniversary of the vesting commencement date and 1/48th vesting each month thereafter over the remaining three years, subject to Mr. Schilke's Continuous Service (as defined in the Plan) through each such vesting date. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 20:31 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-18-000112 · wf-form4_154164068216658.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 F1 · shares: The shares subject to the Restricted Stock award shall vest in four (4) equal annual installments beginning from December 15, 2018, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Inducement Plan(the "Plan")) on each vesting date. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 16:20 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $10.64 | $0.00 |
DisclosureSEC source: 0001140361-18-030425 · doc1.xml · derivative · entry 3 Schilke Tobin · CIK 0001678984 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2028-02-08 F1 · kind: On February 8, 2018, the issuer granted the reporting person Restricted Stock Units ("RSUs") and a stock option that each vest upon the achievement of certain milestones. On June 26, 2018, one of the milestones was achieved, resulting in vesting of a portion of the RSUs and shares subject to the option. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 16:20 UTC | Achaogen, Inc. AKAO · Entity 158957 | SaleCommon Stock | 298 | $9.59 | $2,857.82 |
DisclosureSEC source: 0001140361-18-030425 · doc1.xml · nonDerivative · entry 2 Schilke Tobin · CIK 0001678984 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,748 F3 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of RSUs of the Issuer. F2 · balance_after: Includes 31,730 RSUs. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 16:20 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantCommon Stock | 860 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-030425 · doc1.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,046 F1 · kind: On February 8, 2018, the issuer granted the reporting person Restricted Stock Units ("RSUs") and a stock option that each vest upon the achievement of certain milestones. On June 26, 2018, one of the milestones was achieved, resulting in vesting of a portion of the RSUs and shares subject to the option. F2 · balance_after: Includes 31,730 RSUs. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 17:03 UTC | Achaogen, Inc. AKAO · Entity 158957 | SaleCommon Stock | 2,087 | $11.95 | $24,939.65 |
DisclosureSEC source: 0001140361-18-028440 · doc1.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,186 F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") of the Issuer. F2 · balance_after: Includes (i) 31,730 RSUs and (ii) 2,208 shares acquired under the issuer's Employee Stock Purchase Plan on May 31, 2018. Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 20:38 UTC | Achaogen, Inc. AKAO · Entity 158957 | SaleCommon Stock | 1,108 | $10.67 | $11,822.36 |
DisclosureSEC source: 0001140361-18-009970 · doc1.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,185 F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") of the Issuer. F2 · balance_after: Includes (i) 1,174 shares acquired under the issuer's Employee Stock Purchase Plan on November 30, 2017 and (ii) 30,225 Restricted Stock Units. Read SEC document |
| February 08, 2018 Filed May 15, 2018 18:33 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $10.64 | $0.00 |
DisclosureSEC source: 0001140361-18-024054 · doc1.xml · derivative · entry 2 Schilke Tobin · CIK 0001678984 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2028-02-08 F3 · derivative.exercise_date: The shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of February 8, 2018, subject to the reporting person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| February 08, 2018 Filed May 15, 2018 18:33 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantCommon Stock | 6,880 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-024054 · doc1.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,065 F1 · shares: Grant of Restricted Stock Units ("RSUs"). The reporting person is entitled to one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. F2 · balance_after: Includes 37,105 Restricted Stock Units. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 19:39 UTC | Achaogen, Inc. AKAO · Entity 158957 | SaleCommon Stock | 2,066 | $21.53 | $44,480.98 |
DisclosureSEC source: 0001140361-17-025045 · doc1.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,119 F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") of the Issuer. F2 · balance_after: Includes (i) 32,925 RSUs and (ii) 2,640 shares acquired under the issuer's Employee Stock Purchase Plan on May 31, 2017. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 20:13 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantStock Option (Right to Buy) · Derivative | 12,600 | $0.00 Strike: $23.62 | $0.00 |
DisclosureSEC source: 0001140361-17-009245 · doc1.xml · derivative · entry 3 Schilke Tobin · CIK 0001678984 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,600 Underlying: Common Stock · 12,600 shares Expires 2026-02-22 F4 · derivative.exercise_date: The shares subject to the option shall vest on the following schedule: (i) 40% of the shares subject to the option will vest on the 30th consecutive date that the closing trading price of the Issuer's common stock first reaches or exceeds $30.00 per share; (ii) 40% of the shares subject to the option will vest on the 30th consecutive date that the closing trading price of the Issuer's common stock first reaches or exceeds $40.00 per share; and (iii) 20% of the shares subject to the option will vest on the 30th consecutive date that the closing trading price of the Issuer's common stock first reaches or exceeds $55.00 per share, subject to the reporting person's continued employment or service relationship with the Issuer on each such vesting date and as appropriately adjusted for stock splits, stock dividends, recapitalizations and the like. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 20:13 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantStock Option (Right to Buy) · Derivative | 50,400 | $0.00 Strike: $23.62 | $0.00 |
DisclosureSEC source: 0001140361-17-009245 · doc1.xml · derivative · entry 2 Schilke Tobin · CIK 0001678984 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,400 Underlying: Common Stock · 50,400 shares Expires 2026-02-22 F3 · derivative.exercise_date: The shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of February 22, 2017, subject to the reporting person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 20:13 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantCommon Stock | 13,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-009245 · doc1.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,545 F1 · shares: Grant of Restricted Stock Units ("RSUs"). The reporting person is entitled to one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. F2 · balance_after: Includes 38,300 RSUs. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 21:38 UTC | Achaogen, Inc. AKAO · Entity 158957 | SaleCommon Stock | 955 | $16.78 | $16,024.90 |
DisclosureSEC source: 0001140361-17-003552 · doc1.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,045 F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units of the Issuer. F2 · balance_after: Includes 24,800 Restricted Stock Units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.